Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Alkem Labs shares in focus as Goldman, Morgan Stanley, others purchase stake in Rs 930-crore block deal
Shares of Alkem Laboratories will be in focus after block deals worth around Rs 930 crore saw 17.88 lakh shares traded at Rs 5,200 apiece on Tuesday. Promoter-linked entities offloaded their stake, while domestic mutual funds and foreign institutional investors emerged as key buyers, signalling strong institutional participation. The company also launched semaglutide pre-filled syringes in India.
Alkem Labs sees Rs 930 crore block deal as promoter family entities pare stake; Goldman, Morgan Stanley among key buyers
Alkem Laboratories shares experienced significant block deals totaling Rs 930 crore. Promoter family entities divested shares to a group of domestic mutual funds and foreign institutional investors. This transaction occurred after a strong performance by Alkem Laboratories shares over the past year. The deal highlights continued institutional interest in the pharmaceutical sector.
Dr Reddy's shares in focus after Q4 net profit tumbles 86% YoY; Morgan Stanley, Goldman Sachs weigh in
Dr. Reddy's Laboratories shares: The pharma major posted a sharp 86% YoY drop in Q4FY26 consolidated net profit to Rs 221 crore, compared with Rs 1,587 crore a year ago. Following the weak earnings performance, several brokerages cut their target prices on the stock.
Explained — Key factors behind the surge of up to 15% in power stocks led by NTPC Green Energy
Brokerage firm Morgan Stanley in a note wrote that thermal coal-based power generation could take incremental load due to the surge in power demand and that such a move would support a smoother ramp-up in thermal coal power.